Results 91 to 100 of about 1,524,954 (299)

Dermatologic adverse events of checkpoint inhibitors: What an oncologist should know

, 2016
Immune checkpoint inhibitors (ICI) represent a new revolutionary weapon in the armamentarium of anti-cancer therapies. The side effects of these new agents represent a new challenge for oncologists; they are usually unpredictable and sometimes life ...
Kourie Hampig, Raphael, Habre, Samer Bassilios, Habre, Maya   +2 more
core   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Ustekinumab-induced Henoch-Schönlein purpura in Crohn’s disease: a case report and literature review [PDF]

Intestinal Research
Crohn’s disease is a chronic inflammatory disease of the digestive tract with extraintestinal manifestations, which include skin conditions, arthritis, ocular inflammation, and several autoimmune conditions. Dermatologic manifestations in Crohn’s disease
Merih Deniz Toruner, Tugce Guvenir, Volkan Yilmaz, Ramazan Erdem Er, Murat Toruner   +4 more
doaj   +1 more source

Manual Of Dermatologic Therapeutics With Essentials Diagnosis

, 1974
vii.377 hal22 ...
Arndt A. Kenneth
core  

Lasers for Other Specific Dermatologic Disorders

, 2019
This chapter discusses some of the most common pediatric disorders for which laser or light therapy is a treatment option. These pediatric disorders include alopecia areata (AA), vitiligo, psoriasis, molluscum contagiosum (MC), morphea, atopic dermatitis,
Falto‐Aizpurua, Leyre, Arora, Harleen, Robert D. Griffith, Abyaneh, Mohammad‐Ali Yazdani, Mohammad-Ali Yazdani Abyaneh, Rajabi‐Estarabadi, Ali, Nouri, Keyvan, Leyre Falto-Aizpurua, Ali Rajabi-Estarabadi, Harleen Arora, Keyvan Nouri, Griffith, Robert D   +11 more
core   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-Analysis

Dermatology and Therapy
Introduction For some patients with plaque psoriasis (PsO), a rapid response (i.e. short interval to time to onset of action [TOA]) is desired. The primary objective was to determine average time to achieve a Psoriasis Area and Severity Index (PASI) 90 ...
Kim A. Papp, Ron Vender, Kerri Purdy, Fiona Lovegrove, Irina Oroz, Parbeer Grewal, Perla Lansang, Laura Park-Wyllie, Nastaran Abbarin, Ya-Wen Yang, Becky Hooper, Sandra Vigelis, Tim Disher, Richard G. Langley   +13 more
doaj   +1 more source

Biologics in dermatology: An integrated review

Indian Journal of Dermatology, 2014
The advent of biologics in dermatologic treatment armentarium has added refreshing dimensions, for it is a major breakthrough. Several agents are now available for use.
Virendra N Sehgal, Deepika Pandhi, Ananta Khurana   +2 more
doaj   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Characterization of patients with skin cancer and other affections caused by photodamage

Medisan, 2022
Introduction: Photodamage is the aggression caused by solar radiation in the skin. In turn, the ultraviolet radiation is one of the first agents considered as cancer generators.
Orquídea Isabel Alomá Magariños, Katiuska Tamayo Mariño, Josefa Eugenia Ruz Dominguez   +2 more
doaj